J&J stands by sales growth ambitions—and points to potential Tremfya boon—as Stelara biosimilars take hold
22nd January 2025 Uncategorised 0As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & Johnson is confident it can eke out revenue growth this year. More: J&J stands by sales growth ambitions—and
read more